Research Paper Volume 13, Issue 21 pp 24136—24154
Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort
Figure 2. Association of DDR mutations with survival outcome in MSKCC and TCGA cohorts. (A–B) DDR mutations versus survival outcome with univariate analysis and multivariate regression model in the MSKCC cohort; (C–D) DDR mutations versus survival outcome with univariate analysis and multivariate regression model in the TCGA cohort.